A Higher Risk of Acute Rejection of Human Kidney Allografts Can Be Predicted from the Level of CD45RC Expressed by the Recipients' CD8 T Cells

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Ordonez, Laurence ^a,b,c   Bernard, Isabelle ^a,b,c   Chabod, Marianne ^a,b,c   Augusto, Jean François ^d   Lauwers Cances, Valerie ^e   Cristini, Christelle ^e   Cuturi, Maria Cristina ^f   Subra, Jean François ^d   Saoudi, Abdelhadi ^a,b,c  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d UNIVERSITÉ D'ANGERS   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f Centre National de la Recherche Scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CD45RC ANTIGEN; LEUKOCYTE ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ALLOIMMUNITY; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 84880819485     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069791     Document Type: Article

References (53)

1. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P, (1990) T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 322: 510-517. doi:10.1056/NEJM199002223220805. PubMed: 2405272.
2. Cornell LD, Smith RN, Colvin RB, (2008) Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol 3: 189-220. doi:10.1146/annurev.pathmechdis.3.121806.151508. PubMed: 18039144.
3. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, et al. (2000) Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342: 605-612. doi:10.1056/NEJM200003023420901. PubMed: 10699159.
4. Lechler RI, Sykes M, Thomson AW, Turka LA, (2005) Organ transplantation--how much of the promise has been realized? Nat Med 11: 605-613. doi:10.1038/nm1251. PubMed: 15937473.
5. Dantal J, Soulillou JP, (2005) Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 352: 1371-1373. doi:10.1056/NEJMe058018. PubMed: 15800234.
6. Hermiston ML, Xu Z, Weiss A, (2003) CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 21: 107-137. doi:10.1146/annurev.immunol.21.120601.140946. PubMed: 12414720.
7. Penninger JM, Irie-Sasaki J, Sasaki T, Oliveira-dos-Santos AJ, (2001) CD45: new jobs for an old acquaintance. Nat Immunol 2: 389-396. PubMed: 11323691.
8. Tchilian EZ, Beverley PC, (2006) Altered CD45 expression and disease. Trends Immunol 27: 146-153. doi:10.1016/j.it.2006.01.001. PubMed: 16423560.
9. Streuli M, Hall LR, Saga Y, Schlossman SF, Saito H, (1987) Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens. J Exp Med 166: 1548-1566.
10. Thomas ML, (1989) The leukocyte common antigen family. Annu Rev Immunol 7: 339-369. doi:10.1146/annurev.iy.07.040189.002011. PubMed: 2523715.
11. Ordonez L, Bernard I, L'Faqihi-Olive FE, Tervaert JW, Damoiseaux J, et al. (2009) CD45RC isoform expression identifies functionally distinct T cell subsets differentially distributed between healthy individuals and AAV patients. PLOS ONE 4: e5287. doi:10.1371/journal.pone.0005287. PubMed: 19381293.
12. Subra JF, Cautain B, Xystrakis E, Mas M, Lagrange D,et al. (2001) The balance between CD45RChigh and CD45RClow CD4 T cells in rats is intrinsic to bone marrow-derived cells and is genetically controlled. J Immunol 166: 2944-2952. PubMed: 11207243.
13. Xystrakis E, Cavailles P, Dejean AS, Cautain B, Colacios C, et al. (2004) Functional and genetic analysis of two CD8 T cell subsets defined by the level of CD45RC expression in the rat. J Immunol 173: 3140-3147. PubMed: 15322174.
14. Fournie GJ, Cautain B, Xystrakis E, Damoiseaux J, Mas M,et al. (2001) Cellular and genetic factors involved in the difference between Brown Norway and Lewis rats to develop respectively type-2 and type-1 immune- mediated diseases. Immunol Rev 184: 145-160.
15. Spickett GP, Brandon MR, Mason DW, Williams AF, Woollett GR, (1983) MRC OX-22, a monoclonal antibody that labels a new subset of T lymphocytes and reacts with the high molecular weight form of the leukocyte-common antigen. J Exp Med 158: 795-810. doi:10.1084/jem.158.3.795. PubMed: 6224884.
16. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL, (1994) Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 179: 589-600. doi:10.1084/jem.179.2.589. PubMed: 7905019.
17. Fowell D, McKnight AJ, Powrie F, Dyke R, Mason D, (1991) Subsets of CD4+ T cells and their role in the induction and prevention of autoimmunity. Immunol Rev 123: 37-64. doi:10.1111/j.1600-065X.1991.tb00605.x. PubMed: 1684782.
18. Xystrakis E, Bernard I, Dejean AS, Alsaati T, Druet P, et al. (2004) Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset. Eur J Immunol 34: 408-417. doi:10.1002/eji.200324528. PubMed: 14768045.
19. Davies JD, O'Connor E, Hall D, Krahl T, Trotter J, et al. (1999) CD4+ CD45RB low-density cells from untreated mice prevent acute allograft rejection. J Immunol 163: 5353-5357. PubMed: 10553059.
20. Xystrakis E, Dejean AS, Bernard I, Druet P, Liblau R, et al. (2004) Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. Blood 104: 3294-3301. doi:10.1182/blood-2004-03-1214. PubMed: 15271801.
21. Guillonneau C, Hill M, Hubert FX, Chiffoleau E, Hervé C, et al. (2007) CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 117: 1096-1106. doi:10.1172/JCI28801. PubMed: 17404623.
22. Saoudi A, Seddon B, Heath V, Fowell D, Mason D, (1996) The physiological role of regulatory T cells in the prevention of autoimmunity: the function of the thymus in the generation of the regulatory T cell subset. Immunol Rev 149: 196-216. PubMed: 9005215.
23. Powrie F, Mason D, (1990) OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J Exp Med 172: 1701-1708. doi:10.1084/jem.172.6.1701. PubMed: 2258700.
24. Lazarovits AI, Poppema S, Zhang Z, Khandaker M, Le Feuvre CE, et al. (1996) Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature 380: 717-720. doi:10.1038/380717a0. PubMed: 8614467.
25. Zhong RZ, Lazarovits AI, (1998) Monoclonal antibody against CD45RB for the therapy of rejection and autoimmune diseases. J Mol Med 76: 572-580. doi:10.1007/s001090050252. PubMed: 9694434.
26. Pedros C, Papapietro O, Colacios C, Casemayou A, Bernard I, et al. (2013) Genetic control of HgCl2-induced IgE and autoimmunity by a 117-kb interval on rat chromosome 9 through CD4 CD45RChigh T cells. Genes Immun (in press).
27. Sarvetnick N, Shizuru J, Liggitt D, Martin L, McIntyre B, et al. (1990) Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature 346: 844-847. doi:10.1038/346844a0. PubMed: 2118234.
28. Rosenberg AS, Finbloom DS, Maniero TG, Van der Meide PH, Singer A, (1990) Specific prolongation of MHC class II disparate skin allografts by in vivo administration of anti-IFN-gamma monoclonal antibody. J Immunol 144: 4648-4650. PubMed: 2112572.
29. van den Boogaardt DE, van Miert PP, de Vaal YJ, de Fijter JW, Claas FH, et al. (2006) The ratio of interferon-gamma and interleukin-10 producing donor-specific cells as an in vitro monitoring tool for renal transplant patients. Transplantation 82: 844-848. doi:10.1097/00007890-200607152-02349. PubMed: 17006334.
30. Bacchetta R, Bigler M, Touraine JL, Parkman R, Tovo PA, et al. (1994) High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 179: 493-502. doi:10.1084/jem.179.2.493. PubMed: 7905018.
31. Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, et al. (2001) IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 166: 3789-3796. PubMed: 11238621.
32. Kingsley CI, Karim M, Bushell AR, Wood KJ, (2002) CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 168: 1080-1086. PubMed: 11801641.
33. Liu Z, Fan H, Jiang S,. (2013) CD4(+) T-cell subsets in transplantation. Immunol Rev 252: 183-191. doi:10.1111/imr.12038. PubMed: 23405905.
34. Benghiat FS, Charbonnier LM, Vokaer B, De Wilde V, Le Moine A, (2009) Interleukin 17-producing T helper cells in alloimmunity. Transplant Rev (Orlando) 23: 11-18. doi:10.1016/j.trre.2008.08.007. PubMed: 19027613.
35. Yi T, Zhao D, Lin CL, Zhang C, Chen Y, et al. (2008) Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 112: 2101-2110. doi:10.1182/blood-2007-12-126987. PubMed: 18596226.
36. O'Connor W Jr., Kamanaka M, Booth CJ, Town T, Nakae S, et al. (2009) A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 10: 603-609. doi:10.1038/ni.1736. PubMed: 19448631.
37. Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, et al. (2006) Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 203: 2715-2725. doi:10.1084/jem.20061401. PubMed: 17101734.
38. Voo KS, Wang YH, Santori FR, Boggiano C, Arima K, et al. (2009) Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A 106: 4793-4798. doi:10.1073/pnas.0900408106. PubMed: 19273860.
39. Beriou G, Costantino CM, Ashley CW, Yang L, Kuchroo VK, et al. (2009) IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 113: 4240-4249. doi:10.1182/blood-2008-10-183251. PubMed: 19171879.
40. Josefowicz SZ, Lu LF, Rudensky AY, (2012) Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 30: 531-564. doi:10.1146/annurev.immunol.25.022106.141623. PubMed: 22224781.
41. Campbell DJ, Koch MA, (2011) Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 11: 119-130. doi:10.1038/nri2916. PubMed: 21267013.
42. Wood KJ, Bushell A, Hester,. (2012) J Regulatory immune cells in transplantation. Nat Rev Immunol 12: 417-430. doi:10.1038/nri3227. PubMed: 22627860.
43. Sallusto F, Geginat J, Lanzavecchia A, (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22: 745-763. doi:10.1146/annurev.immunol.22.012703.104702. PubMed: 15032595.
44. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A, (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712. doi:10.1038/44385. PubMed: 10537110.
45. Adams AB, Williams MA, Jones TR, Shirasugi N, Durham MM, et al. (2003) Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 111: 1887-1895. doi:10.1172/JCI200317477. PubMed: 12813024.
46. Ford ML, Kirk AD, Larsen CP, (2009) Donor-reactive T-cell stimulation history and precursor frequency: barriers to tolerance induction. Transplantation 87: S69-S74. doi:10.1097/TP.0b013e3181a2a701. PubMed: 19424013.
47. Valujskikh A, Lakkis FG, (2003) In remembrance of things past: memory T cells and transplant rejection. Immunol Rev 196: 65-74. doi:10.1046/j.1600-065X.2003.00087.x. PubMed: 14617198.
48. Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, et al. (2003) Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 112: 101-108. doi:10.1172/JCI200317601. PubMed: 12840064.
49. Chen BJ, Deoliveira D, Cui X, Le NT, Son J, et al. (2007) Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood 109: 3115-3123. PubMed: 17148592.
50. Zheng H, Matte-Martone C, Li H, Anderson BE, Venketesan S, et al. (2008) Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 111: 2476-2484. doi:10.1182/blood-2007-08-109678. PubMed: 18045967.
51. Foster AE, Marangolo M, Sartor MM, Alexander SI, Hu M, et al. (2004) Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion. Blood 104: 2403-2409. doi:10.1182/blood-2003-12-4431. PubMed: 15231569.
52. Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, et al. (2010) Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 120: 1848-1861. doi:10.1172/JCI39922. PubMed: 20501943.
53. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, et al. (2010) Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 120: 1836-1847. doi:10.1172/JCI39933. PubMed: 20501946.